Research and development expenses for the fourth quarter remained stable at $2.3 million, while general and administrative expenses decreased to $1.5 million from $5.2 million in the prior year, primarily due to a reduction in nonrecurring transaction costs associated with the merger with Pharmagesic (Holdings) Inc. in October 2024. The company highlighted that it has successfully recruited 143 patients for its ongoing Halneuron Phase 2b trial and has commenced a Phase 2b extension trial. Additionally, Dogwood secured financing of up to $26.9 million to support its operations through the Phase 2b final data readout expected later this year.
The company’s cash and cash equivalents totaled $6.5 million as of December 31, 2025, which, along with the recent financing, is anticipated to fund operations through the Halneuron Phase 2b final data readout and into the fourth quarter of 2026. Dogwood Therapeutics continues to focus on developing innovative treatments for pain and neuropathic disorders, with its lead product candidate, Halneuron, receiving fast track designation from the FDA for the treatment of chemotherapy-induced neuropathic pain (CINP). The company remains optimistic about its strategic outlook and operational execution as it progresses through its clinical trials.
